Inmular®：Clulevibart injection

Inmular^®：Clulevibart injection

Indications：

For the prevention of lower respiratory tract infections (LRTIs) caused by respiratory syncytial virus (RSV) in neonates and infants with a gestational age of ≥35 weeks who are entering or born during their first RSV season, excluding children with chronic lung disease (CLD), including bronchopulmonary dysplasia (BPD), or clinically significant congenital respiratory tract abnormalities.

As the first approved domestically developed long-acting monoclonal antibody for RSV prevention in China, Inmular® provides sustained protection throughout the RSV season following a single intramuscular injection in neonates and infants. Its approval marks a new stage in infant RSV prevention in China, transitioning from reliance on imported products to domestic innovation and improved accessibility.

Telephone: 025-85566666

Address: 699-18 Xuanwu Avenue Nanjing China

Zipcode：210042

Fax：025-85471729

Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345
Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate)
© Copyright 2026 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.